Possible pharmacogenetic factors in clozapine treatment failure: a case report

Eromona Whiskey, Graziella Romano, Matilda Elliott, Malcolm Campbell, Cholan Anandarajah, David Taylor and Koravangattu Valsraj

Abstract: There is still much to learn about the predictors of therapeutic response in psychiatry, but progress is gradually being made and precision psychiatry is an exciting and emerging subspeciality in this field. This is critically important in the treatment of refractory psychotic disorders, where clozapine is the only evidence-based treatment but only about half the patients experience an adequate response. In this case report, we explore the possible biological mechanisms underlying treatment failure and discuss possible ways of improving clinical outcomes. Further work is required to fully understand why some patients fail to respond to the most effective treatment in refractory schizophrenia. Therapeutic drug monitoring together with early pharmacogenetic testing may offer a path for some patients with refractory psychotic symptoms unresponsive to clozapine treatment.

Keywords: case report, clozapine, pharmacogenetics, plasma level, schizophrenia, therapeutic drug monitoring

Received: 9 April 2021; revised manuscript accepted: 18 June 2021.

Background
About a third of patients with schizophrenia are refractory to conventional antipsychotic treatments.1,2 For these patients, clozapine is the only evidence-based and licensed treatment. There is now some understanding of the neurobiological basis of treatment resistance,3 but efforts to understand why clozapine is uniquely effective still proves elusive. Although there are possible candidates, no consistent predictors of clozapine response have been identified. Investigation of various clinical, demographic, neuroimaging and genetic predictors of clozapine response have yielded inconclusive results.4,5 There is some evidence that clozapine plasma levels greater than 350 µg/L predict response, but contradictory data exist.6,7 Several guidelines advocate clozapine therapeutic drug monitoring because of the significant inter-individual variation that exists in clozapine metabolism and pharmacokinetics.8 Genetic and environmental factors contribute to this variation, which may ultimately determine the clinical outcome in patients with refractory psychotic disorders.

Case presentation
The patient is a 22-yea-old Black British male diagnosed with treatment-resistant schizoaffective disorder. The onset of his illness was at age 16 years, just before his General Certificate of Secondary Education examinations. His first psychiatric admission, in the same year, was to the adolescent unit where he was treated with risperidone and olanzapine. He was then switched to olanzapine, to which he showed some response but experienced weight gain. He was then trialled on lurasidone, on which he was maintained for some response but failed to respond. He was then switched to olanzapine, to which he showed some response but experienced weight gain. He was then trialled on lurasidone, on which he was maintained for some response but failed to respond. He was then switched to olanzapine, to which he showed some response but experienced weight gain. He was then trialled on lurasidone, on which he was maintained for some response but failed to respond.

Correspondence to:
Eromona Whiskey Pharmacy Department, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, SE5 8AZ, UK
Graziella Romano Matilda Elliott Malcolm Campbell Cholan Anandarajah Koravangattu Valsraj South London and Maudsley NHS Foundation Trust, London, UK
David Taylor Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK
Institute of Pharmaceutical Sciences, King’s College London, UK
NIHR Biomedical Research Centre for Mental Health, South London and Maudsley NHS Foundation Trust, London, UK
religious delusions, paranoid delusions, and delusions of reference and auditory hallucinations. Based on this, our patient met the consensus criteria for treatment resistance.9

The clozapine dose was gradually increased until a dose of 850 mg daily was reached. There was little change in clozapine levels between his dose at 500 mg and that at 850 mg daily, averaging 240 µg/L. He was eventually discharged to the home treatment team, with intensive input and daily reviews at home. At discharge, he was prescribed clozapine 850 mg daily and lithium 1200 mg daily (plasma level of 0.7 mmol/L). Although there was some improvement in his symptoms at discharge, 2 months later, he was referred to the Treatment Review & Assistance Team (TREAT)10 service because of persistent paranoid delusions, thought disorder and disinhibited behaviour. The TREAT service at the South London and Maudsley NHS Foundation Trust provides specialist treatments for patients with ongoing or difficult to treat symptoms and investigates the causes of non-response. All investigations, including magnetic resonance imaging and autoantibodies, were within normal limits. It was suggested that clozapine levels should be optimised to between 350 µg/L and 500 µg/L,11 although how this was to be achieved was not stated.

The following year, there was a major deterioration in his mental health, resulting in another hospital admission. He was eventually transferred to our Psychiatric Intensive Care Unit (PICU) as he became increasingly sexually disinhibited, thought disordered, verbally and physically aggressive, and unmanageable on an open ward. At this point, the clozapine dose was 850 mg daily. During the admission, clozapine was increased further to 950 mg (50 mg above the maximum British National Formulary permitted dose) due to persistently low clozapine levels. The graph of clozapine dose and plasma levels is presented in Figure 1. Questions about compliance were raised and he was put on enhanced nursing observations that confirmed that he was compliant with treatment. Meanwhile, clozapine levels remained largely unchanged at an average of 250 µg/L despite dose increments. He was not on any coprescribed medication known to affect clozapine metabolism; he was also a non-smoker.

For several months during the admission, the patient remained profoundly psychotic as evidenced by hallucinatory and bizarre behaviour, running in the corridors naked, dancing in front of the camera and speaking to the closed-circuit television. Clinical assessment at 6 months of admission showed a Positive and Negative Syndrome Scale (PANSS) score of 109. Transfer out of PICU was impossible because of the nature and degree of his psychotic symptoms. Owing to the persistently low clozapine levels and lack of clinical improvement, the team decided to request a genetic test.

A genetic test was performed by Genomind® Professional PGx™, the summary results of which are displayed in Table 1 below.
Based on the results of the pharmacogenetic profile, we decided to give an empirical trial of fluvoxamine, a potent inhibitor of CYP 450 1A2 and 2C19, but with some activity on other CYP 450 enzymes. Fluvoxamine was initiated and kept at 25 mg daily throughout the period. The baseline clozapine level was 250 µg/L at a daily dose of 950 mg daily. The clozapine level was determined 12-h post-dose three times weekly using the Mycare™ point-of-care testing for clozapine.

Assessments
At the end of 1 week, clozapine levels had risen by 80% to an average of 450 µg/L and remained stable over the next 4 weeks (see Figure 1). There was no evidence of increased adverse effects as assessed using the Glasgow antipsychotic side-effects scale for clozapine. Clinical assessment at 8 weeks showed significant improvement in psychotic symptoms and previously described behaviours substantially reduced with a 33% reduction in a PANSS score to 73, corresponding to an improvement from severely ill to moderately ill or approximating to a 2-point change in Clinical Global Impression scores.

Discussion
The superior efficacy of clozapine in treatment refractory schizophrenia (TRS) is unquestionable. However, even with clozapine, only about half of those with TRS achieve a satisfactory response. Hence, clozapine augmentation with a second antipsychotic is routine clinical practice, despite limited evidence. Data indicate that patients with TRS have normal dopamine function but elevated glutamate levels; however, neither the precise neurobiological mechanisms that underlie the superior efficacy of clozapine in patients with TRS nor definitive determinants of response to clozapine have been clearly identified.

Among the various possible determinants of clozapine treatment response is clozapine plasma levels, which are roughly related to dose, but there is significant inter-individual (up to 45-fold) variation in plasma levels on the same dose. About 50% of this variation in plasma levels can be explained by the dose, patient’s age, sex, body weight, smoking status and the clozapine metabolic ratio. Our patient is a non-smoker. Evidence from the literature suggests that clozapine plasma levels greater than 350 µg/L are associated with clinical response. Therefore, in our patient, treatment failure could be attributed, at least in part, to inadequate clozapine plasma levels.

Clozapine is metabolised primarily by CYP1A2 and 3A4, and to some extent by CYP2C19 and 2D6. However, CYP 1A2 appears to be the main route of clozapine metabolism. This is evidenced by the well-documented and clinically significant interaction and occasional toxicity observed in reported interactions between clozapine and CYP 1A2 inhibitors such as fluvoxamine. Induction of CYP 1A2 by smoking reduces clozapine levels and a significant increase leading to toxicity has been seen when people

### Table 1. Results of genetic test.

| Gene          | Activity                        | Therapeutic implication | Comments                      |
|---------------|---------------------------------|-------------------------|-------------------------------|
| CYP 1A2       | Normal activity                 | Clozapine ↔             |                               |
| CYP 3A4       | High activity metaboliser       | Risk of clozapine ↓     | A dose adjustment may be considered |
| CYP 2C19      | Intermediate metaboliser        | Risk of clozapine ↑     | A dose adjustment may be considered |
| CYP 2D6       | Intermediate metaboliser        | Risk of clozapine ↑     | A dose adjustment may be considered |
| UGT 1A4       | Ultra-rapid metaboliser         | Risk of clozapine ↓     | A dose adjustment may be considered |
| ABCB1 (rs2032583) | Altered gut and brain absorption/penetration | Reduced brain penetration. | May predict poor clozapine response |
stop smoking.31,32 The effect and clinical consequences of inhibition of CYP 2D6, 3A4 and 2C19 on clozapine kinetics seem to be relatively modest.33–35

The pharmacogenetic profile of our patient showed normal activity at CYP 1A2, indicating no effect on clozapine metabolism and intermediate activity at CYP 2D6 and 2C19 that may, potentially, cause an increase in clozapine plasma levels. Perhaps of some relevance is the CYP 3A4 activity, where the patient is reported to show high activity metaboliser status that could potentially reduce clozapine levels. Although our patient had normal CYP 1A2 activity, we chose to use fluvoxamine because of its broad-spectrum activity on CYP 450 enzymes that could, potentially, affect clozapine metabolism.36 Approximately 70% of the variation in clozapine clearance is due to CYP 1A2 activity;37 hence, theoretically, up to a 10-fold increase in clozapine levels can be observed with fluvoxamine addition.28 In our patient, unsurprisingly, we observed only a modest 80% increase in clozapine levels because of normal activity at CYP 1A2. It should be noted, however, that we used only 25mg fluvoxamine and the effect is dose-dependent.

Of note is that our patient is an ultra-rapid metaboliser at UGT 1A4, which may also explain, in part, the observed low clozapine levels, although this is hypothesised to have a greater effect on norclozapine rather than clozapine levels. UDP-glucuronosyltransferase (UGT) enzymes comprise a family of proteins expressed in the liver that catalyse the glucuronidation of various drugs, including clozapine.38,39 Although it has been recognised, not much has been published on the role of and clinical significance of UGT enzymes in clozapine metabolism.40–42 Interestingly, many foods and medicinal plants contain ursolic acid and oleanolic acid, both of which can inhibit UGT1A4 activity and, therefore, have the potential to affect clozapine metabolism.43

ABCB1 is a transmembrane transporter that is expressed in excretory organs such as the kidneys and liver, in intestinal mucosa and on the blood–brain barrier.44,45 In a study of patients with TRS, the presence of a specific genotype of ABCB1 was associated with therapeutic response.46 Indeed, in a systematic review of gene polymorphisms potentially related to the pharmacokinetics of clozapine, the only gene polymorphism that has been found to be associated with clozapine plasma concentration and the therapeutic response was the ABCB1 gene.47 In our patient, ABCB1 (rs2032583) is present. The potential contribution of this genetic variant on either the clozapine levels or the therapeutic response in our patient is unclear.

There is no doubt that the clozapine response is determined, to some extent, by genetic variability involved in its pharmacokinetic and pharmacodynamic characteristics. Some serotonin genes, i.e. HTR2A rs6314, rs6314 and HTR3A rs1062613, may be associated with the response.48 The role of other genetic determinants in clozapine response, such as the nuclear factor 1 B-type,49 is an exciting and developing area, but a full review is beyond the scope of this case report. Further, recent research suggests that polymorphisms at CYP 450 2C19 influence clozapine treatment response.50

Several case reports and clinical studies where fluvoxamine has been used to increase clozapine levels have been published. These have been systematically reviewed.37 This case is unique because the genetic profile of our patient demonstrates normal CYP 1A2 activity, resulting only in a modest rise in clozapine levels. It further shows that it is not clozapine plasma levels per se that makes the difference, but the amount of drug that enters the brain.

The possibility of other factors contributing to clozapine non-response in our patient cannot be ruled out. His illness started at a relatively young age and the age of onset of illness has been suggested as a predictor of response.51 A more recent meta-analysis, however, did not find an association between the age of onset of illness and the therapeutic response to clozapine but, rather, a younger age may be associated with a better clinical response.52 Delay in initiating clozapine is associated with poorer outcomes.53–55 It could be argued that there was some delay in clozapine initiation in our patient.

The prognosis for our patient is positive as his mental state continues to improve. He has a keen interest in mathematics and the sciences, engages well with occupational therapy and psychology and, most importantly, enjoys the support and encouragement of his family. Finally, although the role of pharmacogenetic testing was significant in our case, it must be borne in mind that the availability of testing in psychiatric clinics is still limited. We have used a commercially available test that may not provide a complete pharmacogenetic
profile. These, however, should not preclude the use of fluvoxamine as an adjunct to optimise clozapine treatment in patients with low clozapine plasma levels.

Conclusion
Clozapine is the only evidence-based treatment in refractory schizophrenia. Unfortunately, almost half the patients fail to respond adequately. In addition, clozapine levels can be difficult to predict but optimising plasma levels can contribute to improving chances of successful clinical outcomes. The use of point-of-care finger prick testing for rapid therapeutic drug monitoring and pharmacogenetic testing may turn some clozapine non-responders into responders. It is our earnest expectation that personalised precision psychiatry is not a distant dream.

Acknowledgements
We thank our patient and his family, from whom we obtained permission, to share this learning. We thank our team and colleagues for their support in the care of the patient.

Authors’ contributions
EW compiled the initial draft. GR and KV made substantial contributions in revising the manuscript critically. DT supplied important intellectual content. KV was the lead clinician and EW, GR, MC, CA and ME were all directly involved in the treatment of the patient. All authors have read and approved the final manuscript.

Consent for publication
We obtained signed informed consent from the patient and his family for the publication of this report.

Conflict of interest statement
The authors declare that there is no conflict of interest.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs
Eromona Whiskey https://orcid.org/0000-0002-6146-0073
David Taylor https://orcid.org/0000-0002-2557-1710

References
1. Hasan A, Falkai P, Wobrock T, et al.; WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318–378.
2. Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry 2016; 73: 199–210.
3. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014; 75: e11–e13.
4. Samanaite R, Gillespie A, Sendt KV, et al. Biological predictors of clozapine response: a systematic review. Front Psychiatry 2018; 9: 327.
5. Nielsen J, Nielsen RE and Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 2012; 32: 678–683.
6. Spina E, Avenoso A, Facciolà G, et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 2000; 148: 83–89.
7. Schulte PF. What is an adequate trial with clozapine? Clin Pharmacokinet 2003; 42: 607–618.
8. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9–62.
9. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216–229.
10. Beck K, McCutcheon R, Bloomfield MA, et al. The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatr Scand 2014; 130: 427–438.
11. Taylor D, Barnes TRE and Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. Newark, NJ; John Wiley & Sons, 2018.
12. Salamone S, Sumanth A, Kozo D, et al. 878 point of care testing for clozapine. Eur Neuropsychopharmacol 2019; 29: S584–S585.

13. Hynes C, Keating D, McWilliams S, et al. Glasgow antipsychotic side-effects scale for clozapine – development and validation of a clozapine-specific side-effects scale. Schizophr Res 2015; 168: 505–513.

14. Sikind D, McCartney L, Goldschlager R, et al. Clozapine v. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–392.

15. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–951.

16. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019; 76: 1052–1062.

17. Sikind D, Sikind V and Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. Can J Psychiatry 2017; 62: 772–777.

18. Shah P, Iwata Y, Brown EE, et al. Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. Eur Arch Psychiatry Clin Neurosci 2020; 270: 11–22.

19. Taylor DM, Smith L, Gee SH, et al. Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 2012; 125: 15–24.

20. Barnes TR, Leeson V, Paton C, et al. Amsulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Ther Adv Psychopharmacol 2018; 8: 185–197.

21. Bartoli F, Crocamo C, Di Brita C, et al. Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: a meta-analysis. J Psychiatr Res 2019; 108: 24–33.

22. Mouchlianitis E, Bloomfield MA, Law V, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull 2016; 42: 744–752.

23. Rajkumar AP, Poonkuzhal B, Kuruvilla A, et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013; 28: 50–56.

24. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70–78.

25. Nielsen J, Damkier P, Lublin H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand 2011; 123: 411–422.

26. Olesen OV and Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823–832.

27. Chetty M and Murray M. CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 2007; 8: 307–313.

28. Jerling M, Lindström L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368–374.

29. Koponen HJ, Leinonen E and Lepola U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996; 6: 69–71.

30. Heeringa M, Beurskens R, Schouten W, et al. Elevated plasma levels of clozapine after concomitant use of fluvoxamine. Pharm World Sci 1999; 21: 243–244.

31. Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27: 539–543.

32. Cormac I, Brown A, Creasey S, et al. A retrospective evaluation of the impact of total smoking cessation on psychiatric inpatients taking clozapine. Acta Psychiatr Scand 2010; 121: 393–397.

33. Wetzel H, Anghelescu I, Szegedi A, et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18: 2–9.
34. Raaska K and Neuvonen PJ. Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. *Eur J Clin Pharmacol* 1998; 54: 167–170.

35. Migliardi G, D’Arrigo C, Santoro V, et al. Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. *Clin Neuropharmacol* 2007; 30: 107–113.

36. Olesen OV and Linnet K. Fluvoxamine-clozapine drug interaction: inhibition in vitro of five cytochrome P450 isoforms involved in clozapine metabolism. *J Clin Psychopharmacol* 2000; 20: 35–42.

37. Polcwiartek C and Nielsen J. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. *Psychoparmacology* 2016; 233: 741–750.

38. Benoit-Biancamano MO, Adam JP, Bernard O, et al. A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. *Pharmacogenet Genomics* 2009; 19: 945.

39. Erickson-Ridout KK, Sun D and Lazarus P. Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A (TA) 7TAA and UGT1A4 L48V polymorphisms. *Pharmacogenet Genomics* 2012; 22: 561.

40. Lu D, Xie Q and Wu B. N-glucuronidation catalyzed by UGT1A4 and UGT2B10 in human liver microsomes: assay optimization and substrate identification. *J Pharm Biomed Anal* 2017; 143: 692–703.

41. Mori A, Maruo Y, Iwai M, et al. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. *Drug Metab Dispos* 2005; 33: 672–675.

42. Ghotbi R, Mannheimer B, Akhillu E, et al. Carriers of the UGT1A1 142T>G gene variant are predisposed to reduced olanzapine exposure – an impact similar to male gender or smoking in schizophrenic patients. *Eur J Clin Pharmacol* 2010; 66: 465–474.

43. Xie H, Wu J, Liu D, et al. In vitro inhibition of UGT1A3, UGT1A4 by ursolic acid and oleanolic acid and drug–drug interaction risk prediction. *Xenobiotica* 2017; 47: 785–792.

44. Piatkov I, Caetano D, Assur Y, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. *Pharmacogenomics Pers Med* 2017; 10: 235.

45. Consoli G, Lastella M, Ciapparelli A, et al. ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. *Pharmacogenomics* 2009; 10: 1267–1276.

46. Naveen M, Patil AN, Pattanaik S, et al. ABCB1 and DRD3 polymorphism as a response predicting biomarker and tool for pharmacogenetically guided clozapine dosing in Asian Indian treatment-resistant schizophrenia patients. *Asian J Psychiatr* 2020; 48: 101918.

47. Krivoy A, Gaughran F, Weizman A, et al. Gene polymorphisms potentially related to the pharmacokinetics of clozapine: a systematic review. *Int Clin Psychopharmacol* 2016; 31: 179–184.

48. Gressier F, Porcelli S, Calati R, et al. Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis. *Eur Neuropsychopharmacol* 2016; 26: 163–185.

49. Smith RL, O’Connell K, Athanasu L, et al. Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients – a genome-wide association study adjusting for smoking habits. *Trans Psychiatry* 2020; 10: 366.

50. Rodrigues-Silva C, Semedo AT, da Silva Neri HF, et al. The CYP2C19* 2 and CYP2C19* 17 polymorphisms influence responses to clozapine for the treatment of schizophrenia. *Neuropsychiatr Dis Treat* 2020; 16: 427.

51. Lieberman JA, Kane JM, Safferman AZ, et al. Predictors of response to clozapine. *J Clin Psychiatry* 1994; 55: 126–128.

52. Okhuijen-Pfeifer C, Sterk AY, Horn IM, et al. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. *Neurosci Biobehav Rev* 2020; 111: 246–252.

53. Yoshimura B, Yada Y, So R, et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. *Psychiatry Res* 2017; 250: 65–70.

54. Úçok A, Çiçekçi U, Karabulut S, et al. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia. *Int Clin Psychopharmacol* 2015; 30: 290–295.

55. Shah P, Iwata Y, Pitman E, et al. The impact of delay in clozapine initiation on treatment outcomes in patients with treatment-resistant schizophrenia: a systematic review. *Psychiatry Res* 2018; 268: 114–122.